CV of Mr' Timm Pfannenschmidt

1
CV of Mr. Timm Pfannenschmidt

• Professional experience
• 1/82 11/83 Regional Business Manager
  for Boehringer Ingelheim in the Near East Area
  Management in Athens / Greece. Responsible for
  Kuwait, Bahrain, Qatar, Dubai, Abu Dhabi, Oman,
  South Yemen
• 3/84 9/86 Head of Administration at
  Boehringer Ingelheim in Lima, Peru
• 10/86 1/92 Managing Director of
  Boehringer Ingelheim in Santiago de Chile
• 2/92 12/96 Regional business manager
  for Brazil, Argentina, Uruguay, Paraguay and
  Chile at Boehringer Ingelheim GmbH in
  Ingelheim / Germany
• 1/97 10/00 Head of Business Unit
  Prescription Medicines at Boehringer Ingelheim
  Colombia
• 11/00 5/03 Director of Boehringer
  Ingelheim International Representative Office in
  Singapore
• 7/03 - President and CEO of Boehringer
  Ingelheim Taiwan

2
Boehringer Ingelheim

• A practical approach to globalization in a
  family owned
• enterprise and what it requires from the
  employees.
• Presented by Timm Pfannenschmidt

3
Boehringer Ingelheim

• Boehringer Ingelheim Taiwan Ltd.
• Jul. 17, 2003
• Boehringer Ingelheim Taiwan Limited, an affiliate
  of the Boehringer Ingelheim Group of companies,
  is one of the 20 leading pharmaceutical companies
  in Taiwan. In 2002, it posted revenues of NT
  1,290 million and employed 260 people.
• Boehringer Ingelheim Taiwan was established in
  1975 with 20 employees. Over the years the
  company developed from an importer of
  pharmaceuticals to a fully fledged pharmaceutical
  company. Today the activities of the company
  embrace marketing, sales as well as distribution
  and production of their products. The
  manufacturing plant is located in Hsin-Chu and
  the majority of products for the Taiwanese market
  are produced here. Several products are exported
  to other Boehringer Ingelheim affiliates.
• Prescription Medicines and Consumer Health Care
  are the core activities.
• In Prescription Medicines Boehringer Ingelheim
  Taiwan has built on the companys traditional
  area of expertise, the cardiovascular and
  respiratory fields
• Actilyse, a recombinant tissue plasminogen
  activator (rt-PA), is a genetically engineered
  version of naturally occurring tissue plasminogen
  activator, which has the biological function of
  removing small clots that routinely form in the
  bloodstream. The drug is already marketed in
  Taiwan for the treatment of acute myocardial
  infarction and pulmonary embolism.

4
Boehringer Ingelheim

• MOBIC is a selective COX-2 inhibitor and
  indicated for the symptomatic treatment of
  painful osteoarthritis, rheumatoid arthritis and
  ankylosing spondylitis. MOBIC has been used by
  more than 70 million patients in 100 countries
  worldwide it offers a balance between reliable
  efficacy and overall safety, including a
  favorable gastrointestinal tolerability profile.
• Micardis is an angiotensin II receptor blocker
  for the treatment of hypertension alone, or in
  combination with other antihypertensive agents.
  Clinical data indicate that the compound has a
  good safety profile and allows excellent control
  of blood pressure over a 24 hour period when
  given once daily - especially in the early hours
  of the morning when patients are at highest risk
  of myocardial events.
• Spiriva, a novel once-daily inhaled COPD
  treatment that works through prolonged
  M3-receptor blockade, it has delivered improved
  breathing for hundreds of thousands of people in
  Europe and around the world. In Taiwan, Spiriva
  will be launched in the end of year 2003.

5
Boehringer Ingelheim

• Consumer Health Care comprises products which
  need no prescription and are chosen by the users
  themselves. The company is active mainly in the
  following product categories
• Natural Health phyto-medicines and
  multivitamin/mineral formulas (Pharmaton,
  Ginsana, Topfit, Topfit Jr., and Gymnefit)
• Cough Cold (Bisolvon)
• In future, the availability of new attractive
  products and services which represent a distinct
  benefit to patients is of particular importance
  to our company.
• For more information on Boehringer Ingelheim,
  please see the international Internet website
  www.boehringer-ingelheim.com